Clinical Trial Update: A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) [Phase 3]

View source ↗

Summary

Phase 3b multicenter trial evaluating intravenous golimumab for rheumatoid arthritis in patients with diminished disease control on infliximab; the study was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Golimumab (golimumab)
• Infliximab (infliximab)

Snippet

Sponsor: Janssen Biotech, Inc. | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: TERMINATED | Results posted: 2017-04-12